

Poster Session A

Sunday, May 19, 2019

12:30 p.m.–3:00 p.m.

A01 Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) for the treatment of bladder cancer. Brittany Bunch, Moffitt Cancer Center, Tampa, FL, USA.

A02 Photodynamic therapy in combination with immunotherapy enhances the long-term cure of bladder cancer in tumored mice. Farukh Durrani, Roswell Park Cancer Institute, Buffalo, NY, USA.

A03, PR04 Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes. Markus Eckstein, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

A04 DNA damage repair gene mutations and associated tumor immune landscape as biomarkers of response to immunotherapy in muscle invasive urothelial cancer. Madhuri Koti, Queen's University, Kingston, ON, Canada.

A05 Expansion of tumor-infiltrating lymphocytes (TIL) using lovance's Gen 2 process from advanced bladder cancer for adoptive immunotherapy. Qiang Li, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A06, PR03 Can immunological biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC?. Melinda Lillesand, Stavanger University Hospital, Stavanger, Rogaland, Norway.

A07 A marker to optimise BCG dosing schedules for immunotherapy. Ratha Mahendran, National University of Singapore, Singapore, Singapore.


A08 Application of Miltuximab®-IRDye800 for near-infrared fluorescence imaging of urothelial carcinoma *in vivo*. Dmitry Polikarpov, Macquarie University, Sydney, NSW, Australia.

A09 Photoimmunotherapy (PIT) for treatment of bladder cancer. Reema Railkar, National Cancer Institute, Bethesda, MD, USA.

A10 Logical modelling of tumor-immune cross-talk network to predict the mechanism of immune evasion in muscle invasive bladder cancer (MIBC). Shruti Shah, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A11 Generation and characterization of immune competent syngeneic model of muscle invasive bladder cancer (MIBC). Shruti Shah, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A12 Bladder cancer derived extracellular vesicles and immune activation. Sin Mun Tham, National University of Singapore, Singapore, Singapore.



Poster Session A

Sunday, May 19, 2019

12:30 p.m.–3:00 p.m.

A13 Entinostat enhances antitumor immune responses and cooperates with PD-1 blockade in bladder cancer mouse models. Andrew Truong, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.

A14 Next-generation sequencing of Bacille Calmette-Guerin (BCG) unresponsive tumors identifies actionable alterations for potential targeted therapy in non-muscle invasive bladder cancer. Aleksandra Walasek, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A15 Uninflamed immunological microenvironment of muscle invasive bladder cancer associates with activating FGFR3 gene alterations. Veronika Weyrerer, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

A16 Characterization of ErbB family expression in intratibial bladder cancer xenografts: Considerations for preclinical modeling. Luke Broses, University of Michigan, Ann Arbor, MI, USA.

A17 Gene expression changes associated with metastasis in mice with bladder cancer. Kesavan Esuvaranathan, National University Health System, Singapore, Singapore.


A18 Targeting epigenetic dysregulation in bladder cancer through inhibition of EZH2. Patricia Keller, Constellation Pharmaceuticals, Inc., Cambridge, MA, USA.

A19 A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC). Timothy Owens, Principia Biopharma, South San Francisco, CA, USA.

A20 Disruption and restoration of pioneer transcription factor function in bladder cancer. Caroline Schuerger, Cleveland Clinic, Cleveland, OH, USA.

A21 TRIM29 promotes invasion and migration of bladder cancer cells by regulating myosin-intermediate filament network and focal adhesion. Yin Wang, University of Michigan, Ann Arbor, MI, USA.

A22 STAG2, a novel genetic regulator of bladder cancer. Anna Woloszynska, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.



Poster Session A

Sunday, May 19, 2019

12:30 p.m.–3:00 p.m.

A23 The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial cancer. Christopher Hoimes, Case Western Reserve University/University Hospitals Seidman Center, Cleveland, OH, USA.

A24 Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of muscle-invasive bladder tumors. Isabelle Bernard-Pierrot, Institut Curie, Paris, France.


A25 Effect of pre-existing conditions on bladder cancer diagnosis: A cohort study using electronic primary care records. Madeline Carney, USF Morsani College of Medicine, Tampa, FL, USA.

A26, PR05 Similarities in molecular subtypes and subtype immune patterns between naturally-occurring canine and human invasive bladder cancer. Deborah Knapp, Purdue University, West Lafayette, IN, USA.

A27 Fidelity of a PDX-CR model for bladder cancer. Abdul Mondal, Georgetown University Medical Center, Washington, D.C., USA.

A28 Deregulation of KMT2D promotes squamous differentiation in a mouse model of muscle-invasive bladder cancer. Lijie Rong, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.

A29 Multiplex functional genomics assay to deconvolute compound genetic drivers of bladder cancer. Alicia Wong, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.



Poster Session B

Monday, May 20, 2019

5:00 p.m.–7:30 p.m.

B01 Validation of a novel cytologic biomarker for urothelial carcinoma. Sruthi Babu, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.

B02 TP63 isoform expression landscape associations with bladder cancer patient outcomes. Armand Bankhead, University of Michigan, Ann Arbor, MI, USA.

B03 Identification of PTEN p.W274C as a potential biomarker to predict inferior survival in patients with limited stage small cell bladder cancer. Earle Burgess, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

B04 Study on screening of new targets, specific recognition and intervention of bladder cancer. Zhiming Cai, Shenzhen University, Shenzhen, Guangdong Province, China.

B05 Basic research and translational medicine of bladder cancer in China. Zhiming Cai, Shenzhen University, Shenzhen, Guangdong Province, China.

B06 Pathological T1 substaging improves the identification of high-risk non-muscle invasive bladder cancer patients at risk of BCG-failure. Florus Christiaan de Jong, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.


B07 A long non-coding RNA-based genomic classifier identifies a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Joep de Jong, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

B08 MSH2 downregulation induces chemoresistance in bladder cancer. Andrew Goodspeed, UC Denver AMC, Denver, CO, USA.

B09, PR08 Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

B10 A simple immunohistochemical algorithm to evaluate molecular subtypes and clinical associations in non-muscle invasive bladder cancer. Chelsea Jackson, Queen's University, Kingston, ON, Canada.

B11 Multi-omic interrogation of gemcitabine and cisplatin resistant bladder cancer cell lines identifies unique and shared mediators of chemosensitivity and resistance. Robert Jones, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.



Poster Session B

Monday, May 20, 2019

5:00 p.m.–7:30 p.m.

B12 Characterization of the global proteome and phosphoproteome in cisplatin resistant bladder cancers revealed the CDK2 network as a potential therapeutic target. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B13 Acetate metabolism mediated by Acetyl-CoA synthetase 2 in cisplatin resistant bladder cancer. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B14 Epigenetic remodeling of cancer metabolisms in cisplatin resistant bladder cancer. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B15 Bladder cancer susceptibility polymorphisms and mortality from non-muscle and muscle invasive bladder cancer. Reno Leeming, Dartmouth College, Hanover, NH, USA.

B16 AGR2 is a marker of disease progression and a potential therapeutic target in non-muscle invasive bladder cancer. Andreia Maia, Champalimaud Centre for the Unknown, Lisbon, Portugal.

B17 Developing a multiplex imaging tool for cellular phenotyping to stratify non-muscle invasive bladder cancer patients. Paul Robson, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.


B18 Molecular classification of NMIBC based on protein abundance. Rafael Stroggilos, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

B19, PR07 The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA. Gillian Vandekerkhove, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.

B20 Characterization of tumor mutational landscape in smokers and non-smokers with urothelial carcinoma. Aleksandra Walasek, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B21 PTRF promotes cell survival and predicts disease progression in upper tract urothelial carcinoma. Hsin-Chih Yeh, Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

B22; PR02 Profiling intra-tumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology. Andries Zijlstra, Vanderbilt University Medical Center, Nashville, TN, USA.



Poster Session B

Monday, May 20, 2019

5:00 p.m.–7:30 p.m.

B23 *FGFR3* mutations and their relation to *FGFR3* expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-*FGFR3* bladder cancer treatment?

Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

B24, PR06 Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC). Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

B25, PR09 Gene expression profiling in wild type and mutant *FGFR3* metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab. Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, MD, US.

B26 EV-301: A Phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy. Amal Melhem-Bertrandt, Astellas Pharma, Inc., Northbrook, IL, USA.

B27 Photoluminescent nanoconjugates for molecular imaging of bladder cancer. Dmitry Polikarpov, Macquarie University, Sydney, NSW, Australia.

B28, PR01 Novel role of ketone body metabolism in acquired gemcitabine resistance. Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, A, USA.

B29 Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy. Philip Abbosh, Fox Chase Cancer Center, Philadelphia, PA, USA.

B30 A living biomarker from urine to predict drug efficacy and recurrence of bladder cancer. Xuefeng Liu, Georgetown University, Washington, D.C., USA.